Industry News
Pharmaceutical Industry News
With an eye on the lucrative U.S….
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster Firdapse for $4.1 billion.
After a surprise rejection in…
After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same single-arm trial that the agency had previously found problematic. The case could reignite investors’ hope of
The FDA has hit Alnylam with an…
The FDA has hit Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech of presenting open-label data that create a misleading impression of the drug’s effects.
Insulet has always been a strong…
Insulet has always been a strong leader in the medtech industry when it comes to its marketing game—and the diabetes device maker isn’t looking to rest on its laurels.
Her Self-Experiment with Drug Detox Almost Broke Her
Against expert advice, people are using new and unpredictable synthetic drugs to experiment on themselves in hopes of becoming free of addiction.
Her Self-Experiment with Drug Detox Almost Broke Her
Against expert advice, people are using new and unpredictable synthetic drugs to experiment on themselves in hopes of becoming free of addiction.
Why AI, point-of-care mindset, and…
Why AI, point-of-care mindset, and coordinated engagement are redefining how pharma brands break through.
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.
A Bristol Myers Squibb plant that makes cancer drugs was the only manufacturer in the U.S. recognized for innovation by the World Economic Forum this year.
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.
A Bristol Myers Squibb plant that makes cancer drugs was the only manufacturer in the U.S. recognized for innovation by the World Economic Forum this year.
Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Some
The drug is for a small subset of patients. But evidence that breathing and strength can get better for some of them is remarkable for a paralyzing, usually fatal disease.
Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Some
The drug is for a small subset of patients. But evidence that breathing and strength can get better for some of them is remarkable for a paralyzing, usually fatal disease.
The FDA’s Commissioner’s National…
The FDA's Commissioner's National Priority Voucher program has been steeped in controversy since its inception. Now, Sanofi has asked that one of its applications be taken out of the fast-track program, according to Stat.
In a bid to better deploy its…
In a bid to better deploy its boots-on-the-ground resources, the FDA is rolling out a new pilot program, under which the regulator is leveraging “one-day inspectional assessments” to complement its traditional site visits.
After several consecutive quarters…
After several consecutive quarters on the backfoot, Danish drug juggernaut Novo Nordisk is receiving warmer feedback on its starting performance in 2026, thanks in no small part to its head start over rival Eli Lilly
The FDA-conducted studies…
The FDA-conducted studies reportedly found COVID vaccines and GSK's shingles vaccine Shringrix safe and effective, according to The New York Times.
Cell and gene therapy developers…
Cell and gene therapy developers must build continuity of engagement to create trust in the modalities, according to a report by Bayer’s venture capital wing.
Following a series of “most…
Following a series of “most favored nation” pricing deals with 17 large pharma companies, the Trump administration released a report Tuesday projecting potential $529 billion in savings from the policy over the next 10 years.
Last month, when Optimi…
Last month, when Optimi Health kicked off an initial public offering of 2.5 million shares, the timing couldn’t have been better for the Vancouver-based manufacturer of psychedelic drugs. With President Donald Trump recently signing an executive order
With commitments to invest more…
With commitments to invest more than $50 billion in building up its U.S. manufacturing presence, Eli Lilly has earmarked an additional $4.5 billion to upgrade two of its three planned production facilities in Lebanon, Indiana.
As the promotion battle between…
As the promotion battle between old rivals Novo Nordisk and Eli Lilly heats up, regulators in France are reminding the world’s two biggest obesity drugmakers what happens when promotion goes too far.